EFFICACY OF TOPICAL MINOXIDIL 5% AND BETAMETHASONE VALERATE 0.1% VERSUS BETAMETHASONE VALERATE 0.1% MONOTHERAPY IN NON-SEGMENTAL VITILIGO
Roshna Ahmed Ali a and Ali Mozan Dhahir El-Ethawi b
a College of Medicine, University of Sulaimani, Kurdistan Region, Iraq.
b Department of Cardiology, Sulaymaniyah Teaching Hospital, Interventional Cardiology Center, Kurdistan Region, Iraq.
Submitted: 17/4/2022; Accepted: 1/8/2022; Published: 21/9/2022
DOI Link: https://doi.org/10.17656/jsmc.10365
Vitiligo is a common depigmentation disorder of the skin. Circumscribed amelanotic patches characterize it due to the destruction of melanocytes. It affects 0.5-2.0% of general population. Many combinations of medical therapies have been studied, but the optimal treatment has yet to be identified.
To evaluate the efficacy of topical minoxidil 5% plus betamethasone valerate 0.1% compared to betamethasone valerate 0.1% monotherapy in the treatment of non-segmental vitiligo
Materials and Methods
This open-label, comparative, therapeutic clinical trial was conducted at the Sulaimani dermatology teaching center from May 2021 to February 2022. In this trial, 30 patients with non-segmental vitiligo were divided into two groups, 15 patients each; group A treated with topical minoxidil 5% spray & betamethasone valerate 0.1% cream, and group B was treated with betamethasone valerate 0.1% cream alone, the two regimens were used twice a day and patients were followed up for three months.
The mean percentage of depigmentation in groups A and B were (21.9%) & (16%), respectively.
Topical minoxidil & betamethasone valerate combination achieved a higher grade of depigmentation, especially in the vitiligo of the hair-bearing areas of the head & neck. However, there was no significant difference compared to betamethasone valerate alone (P value = 0.8).
Topical minoxidil, Non-segmental vitiligo.
1. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015; 386(9988)74-84.
2. Christian Krüger, Karin Uta Schallreuter. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. 2012; 51(10)1206-12.
3. Ali Alikhan, MD. Lesley M. Felsten, MD. Meaghan Daly, MD. Vesna Petronic-Rosic, MD, MSc. Vitiligo: A comprehensive overview. 2011; 65(3) P473-491.
4. Cario-Andre M, Pain C, Gauthier Y, Taieb A. The melanocytorrhagic hypothesis of vitiligo tested on pigmented, stressed, reconstructed epidermis. Pigment Cell Res. 2007; 20, 385-393.
5. Ezzedine K, Gauthier Y, Leute-Labreze C, Marquez S, Bouchtnei S, January T, et al. Segmental vitiligo associated with generalized vitiligo (mixed vitiligo): a retrospective case series of 19 patients. J. Am. Acad. Dermatol.2011; 65, 965-971.
6. Passeron T, Ortonne JP. Vitiligo and Other Disorders of Hypopigmentation. In: Bolognia JL, Schaffer JV, Cerroni L, Editors. Dermatology. 4th ed. ELSEVIER; 2018.p.1087-1095.
7. Mohamed Allam. Hassan Riad. Concise review of recent studies in vitiligo. 2013; 2013(2)1-19.
8. B H Mahmoud, C L Hexsel, I H Hamzavi. An update on new and emerging options for the treatment of vitiligo. 2008; 13(2)1-6.
9. M. D. Njoo; MD. PI Souls, MD; J. D. Bos, MD, PhD; Nonsurgical Repigmentation Therapies in Vitiligo: Meta-analysis of the Literature.1998; 134(12)1532-1540.
10. Veronica Lepe, MD; Benjamin Moncada, MD; Juan Pablo Castanedo-Cazares, MD; A Double-blind Randomized Trial of 0.1% Tacrolimus vs. 0.05% Clobetasol for the Treatment of Childhood Vitiigo.2003; 139(5)581-585.
11. Rossi A, Cantisani C, Melis L, Iorio A, Scali E, Calvieri S. Minoxidil use in dermatology, side effects and recent patents. Recent patents on inflammation & allergy drug discovery. 2012 May 1;6(2):130-6.
12. Blumeyer A, Tosti A, Messenger A, Reygagne P, Del Marmol V, Spuls PI, Trakatelli M, Finner A, Kiesewetter F, Trüeb R, Rzany B. Evidence–based (S3) guideline for the treatment of androgenetic alopecia in women and in men. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2011 Oct;9: S1-57.
13. Cui J, Shen LY, Wang GC. Role of hair follicles in the repigmentation of vitiligo. Journal of investigative dermatology. 1991 Sep 1;97(3):410-6.
14. Nishimura EK, Jordan SA, Oshima H, Yoshida H, Osawa M, Moriyama M, Jackson IJ, Barrandon Y, Miyachi Y, Nishikawa SI. Dominant role of the niche in melanocyte stem-cell fate determination. Nature. 2002 Apr;416(6883):854-60.
15. Bhor U, Pande S. Scoring systems in dermatology. Indian J Dermatology Venereology Leprosy. 2006; 72(4):315-21.
16- Mina, M., Elgarhy, L., Al-said, H., & Ibrahim, Z. Comparison between the efficacy of microneedling combined with 5-fluorouracil vs microneedling with tacrolimus in the treatment of vitiligo. Journal of Cosmetic Dermatology. 2018; 17(5), 744–751.
17. Anstey AVP. Disorder of skin color. In: Burns T, Breathnach S, Cox N, Griffiths C, eds. Rooks Textbook of Dermatology, 8th edn. Oxford, UK: Wiley- Blackwell Publishing; 2010. P. 58. 46- 9.
18. G. Serena, T. Georgi, L. Jacopo, W. Uwe, S. Francesca, R. Miriam, et al. Unconventional treatments for vitiligo; are they (Un) satisfactory. Open Access Maced J Med Sci.2018; 6 (1), 170-175.
19. Srinivas CR, Shenoi SD, Balachandran C, Acceleration of repigmentation in vitiligo by topical minoxidil in patients on photochemotherapy. Int J Dermatol. 1990; 29(2): 154-5.
20. Kanellis VG, Gupta M. Enhanced repigmentation of vitiligo by topical minoxidil and excimer lamp treatment. Pigment International. 2019 Jan 1;6(1):46.
21. KOGA M. Vitiligo: a new classification and therapy. British Journal of Dermatology. 1977 Sep;97(3):255-61.
22. Cohen JL. Enhancing the growth of natural eyelashes: the mechanism of bimatoprost–induced eyelash growth. Dermatologic surgery. 2010 Sep;36(9):1361-71.
23. Khidhir KG, Woodward DF, Farjo NP, Farjo BK, Tang ES, Wang JW, Picksley SM, Randall VA. The prostamide–related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias. The FASEB Journal. 2013 Feb;27(2):557-67.
24.Barbulescu CC, Goldstein NB, Roop DR, Norris DA, Birlea SA.Harnessing the power of regenerative therapy for vitiligo and alopecia areata. Journal of Investigative Dermatology. 2020;140(1):29-37.
25. Grimes PE. Bimatoprost 0.03% Solution for the Treatment of Nonfacial Vitiligo. Journal of Drugs in Dermatology: JDD. 2016 Jun 1;15(6):703-10.
26. Hallaji Z, Ghiasi M, Eisazadeh A, Damavandi MR. Evaluation of the effect of disease duration in generalized vitiligo on its clinical response to narrowband ultraviolet B phototherapy. Photodermatol Photoimmunol Photomed. 2012; 28(3):115-9.
© The Authors, published by University of Sulaimani, College of Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.